The following human
cancer cell lines were used in this study: the colon carcinoma-derived
cell line SW480 and lung fibroblasts WI-38 (obtained from the American
Tissue Culture Collection), the ovarian carcinoma-derived cell line
A2780 (obtained from Sigma-Aldrich), the acute promyelocytic leukemia-derived
cell line HL-60 (obtained from Dr. M. Center, Kansas State University),
the cervix carcinoma-derived cell line KB-3-1 and the colchicine resistant
subline KBC-1 (obtained from Dr. D. W. Shen, Bethesda, Maryland).
SW480 and WI-38 cells were grown in MEM with 10% FCS and A2780, KB-3-1,
KBC-1, and HL-60 cells were cultured in RPMI 1640 supplemented with
10% FCS. SW480/Tria cells were generated by continuous exposure of
SW480 cells to increasing concentrations of Triapine (starting point,
0.05 μM; end point, 20 μM) over a period of one year.19 (link) Triapine was administered to the cells once
every other week at the day after passage, when cells had attached
to the culture flasks.
Synergism is expressed by the combination
index (CI) according to Chou and Talalay49 (link) using CalcuSyn software (Biosoft, Ferguson, MO, USA). CI < 0.9,
CI = 0.9–1.2, or CI > 1.2 represent synergism, additive
effects,
and antagonism, respectively.